跳至主要内容
临床试验/NCT03843593
NCT03843593已完成不适用

Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?

Memorial Sloan Kettering Cancer Center3 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2019年2月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
38
试验地点
3
主要终点
self-reported factors patients consider in deciding whether or not to undergo adjuvant therapy

研究概览

简要总结

The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with stage IIIB, IIIC, IIID, or IV (AJCC, 8th edition) cutaneous melanoma rendered free of disease by surgical resection.
  • Patients are being offered adjuvant nivolumab or pembrolizumab therapy
  • Patient has not yet formally discussed their treatment options with their Medical Oncologist.
  • Age 18 or older.
  • Ability to speak and read English because we do not have the resources to translate materials into other languages.

排除标准

  • Patient not currently free of disease.
  • Candidate for adjuvant dabrafenib/trametinib therapy.
  • Patients who have received prior checkpoint inhibitor therapy.

结局指标

主要结局

self-reported factors patients consider in deciding whether or not to undergo adjuvant therapy

时间窗: 1 year

Factors considered are gleaned from the Acceptance/Declination Survey

次要结局

  • self-reported quality of life(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

A Study To See Why Patients Agree To or Decline To... | 临床试验